entertainment -WSS

entertainment

author：leisure time 2025-08-28 08:40:24 - browse：44358

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Why health records don't always know when patients are dead

WSS

Carvykti CAR

What STAT readers think about the FDA and patient advocacy

Three trends to watch in biotech in 2024

Gilead might be held responsible for not developing a drug

KalVista pill reduced swelling 'attacks' caused by genetic disease

In Spain, a hospital brews its own CAR

focus

entertainment

hotspot

Walensky prepares to leave CDC — and Congress — behind

Biden report: The neurospychology of memory and aging

After affirmative action ruling, medical educators look to 'holistic review'

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Psychedelics group wrestles with new pharma identity

What we’ve learned from the Aduhelm mess

Guidelines to prevent youth baseball injuries need more muscle

What should King Charles tell the public about his cancer?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Keeping primary care docs in field isn't impossible, says AAFP CEO

hotspot

How to keep neuroscience’s past racism from being its future

Gilead might be held responsible for not developing a drug

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Christmas in the PICU brings some surprising joy

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Wikipedia

explore

focus

leisure time